Clinical Trial

Effects of Vaping on Post-operative Recurrence of Crohn's Disease

Study acronym: VAPE-CD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2024 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Tobacco smoke is a well-established risk factor for post-operative recurrence of Crohn's disease. Over the last few decades electronic cigarettes have gained popularity as an alternative to traditional tobacco, however, their effects on Crohn's disease are unknown. Tobacco smoke negatively impacts most outcomes of Crohn's disease including, but not limited to, response to therapy and risk of hospitalization. Smoke is particularly relevant in the post-operative setting, as it increases the chance of disease recurrence after surgical resection, and therefore prophylactic treatment with biologics is recommended in Crohn's patients who smoke. At present, there are no studies evaluating the impact of e-cigarette smoke on post-operative recurrence and therefore informing physicians on the appropriateness of prophylactic treatment in this subset of patients. This study aims to assess the impact of vaping (or smoking of electronic cigarettes) on Crohn's disease endoscopic recurrence after resection as compared to non-smoke and smoke of traditional tobacco cigarettes.
Trial Details
NCT Number NCT06734780
Lead Sponsor IRCCS Ospedale San Raffaele
Conditions The Impact of Vaping on Crohn's Disease Endoscopic Recurrence After Resection
Enrollment 600 participants
Start Date 2024-11-30
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2024-12-16